Track CalciMedica Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CalciMedica Inc. Common Stock CALC · Stock Open CalciMedica Inc. Common Stock in new tab

1.21 USD
EPS
-4.41
P/B
1.97
ROE
-763.32
Beta
1.15
Target Price
42.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-4.41
Book Value0.61
Price to Book1.97
Debt/Equity163.24
% Insiders18.350%
Estimates
Forward P/E-0.74
Forward EPS-1.63
Target Mean Price42.00

DCF valuation

Model fair value for CalciMedica Inc. Common Stock (CALC)
Result
Sign in to run the valuation for CALC.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Strong buy · mean target 42.00 USD (low 9.00, high 75.00) · as of 15 Nov 2026
Low 9.00
Mean 42.00
High 75.00
Price 1.21
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CalciMedica Inc. Common Stock Logo CalciMedica Inc. Common Stock Analysis (CALC)

United States Health Care Official Website Stock

Is CalciMedica Inc. Common Stock a good investment? CalciMedica Inc. Common Stock (CALC) is currently trading at 1.21 USD. Market analysts have a consensus price target of 42.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: CalciMedica Inc. Common Stock is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -1.63.

Investor FAQ

Does CalciMedica Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is CalciMedica Inc. Common Stock?

CalciMedica Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -4.41.

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Exchange Ticker
NMS (United States) CALC
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 20, 2023 0.07
Aug. 31, 2026 1:5
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion